FibroBiologics reported preclinical data showing its thymic organoid platform restored thymic function and generated functional T cells, supporting potential applications in age-related immune decline and cancer.
Written by: Mennatullah Mansour, PharmD
Reviewed By: Pharmacally Editorial Team
FibroBiologics, Inc. reported preclinical findings supporting its proprietary thymic organoid platform designed to restore thymic function and potentially reverse age-related immune decline. The data were presented at the Keystone Symposia on Aging and Immunity, highlighting the platform’s ability to regenerate diverse and functional T cell populations in preclinical models.
The thymus is the primary site for T cell development and plays a central role in adaptive immunity. However, thymic function declines early in life through a process known as thymic involution. By midlife, reduced thymic output leads to diminished immune diversity, impaired immune surveillance, and increased susceptibility to infections, cancer, autoimmune disorders, and weaker vaccine responses.
FibroBiologics developed a transplantable thymic micro-organoid system using selectively screened fibroblasts combined with thymic stromal cells. The organoids are generated using a rapid, three-day, matrix-free culture process and are designed to be cryopreservable and injectable, supporting potential clinical scalability.
In immunodeficient mouse models, transplanted organoids generated multiple T cell lineages, including alpha-beta (αβ) T cells, gamma-delta (γδ) T cells, natural killer T (NKT) cells, and FoxP3+ regulatory T cells. The organoid-derived cells demonstrated a diverse T cell receptor repertoire and functional responses to immune stimuli, indicating biological activity in vivo. Gene expression analysis also confirmed sustained expression of key factors required for T cell development and maturation, suggesting that the organoids replicate core aspects of thymic biology.
In a melanoma model, organoids derived from pmel-1 thymocytes produced antigen-specific T cells that slowed tumor growth in mice. The anti-tumor response was accompanied by enhanced activation of natural killer cells and was observed across tumor sites and draining lymph nodes, indicating a systemic immune effect.
According to Hamid Khoja, the preclinical data demonstrate that fibroblast-based organoids can restore thymic function and generate antigen-specific T cells with anti-tumor activity. He noted that the platform may have potential applications in addressing age-related immune decline, immune recovery following chemotherapy or radiation, and congenital disorders associated with loss of thymic function.
Reference
FibroBiologics Presents Novel Thymus Organoid Platform to Combat Age-Related Immune Decline at Keystone Symposia on Aging and Immunity, 10 April 2026, https://ir.fibrobiologics.com/news-events/press-releases/detail/111/fibrobiologics-presents-novel-thymus-organoid-platform-to-combat-age-related-immune-decline-at-keystone-symposia-on-aging-and-immunity
About the Writer
Mennatullah Mansour is pursuing a PharmD and is based in Alexandria, Egypt. She is driven by a strong passion for continuous learning and professional development, with a focus on pharmaceutical care, patient health, and medication safety. Her interests include prescription processing, patient counseling, and interpreting clinical information. She brings a detail-oriented approach and a strong ability to translate medical knowledge into clear, accurate, and reliable content for healthcare audiences.